Cargando…
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service
BACKGROUND: Patients with genotype-1 hepatitis C virus infection who have failed to respond to standard therapy or who relapse following treatment may be considered for an interferon-free regimen incorporating a nonstructural protein 5A (NS5A) inhibitor. Sustained virologic response (SVR) with these...
Autores principales: | Westerhout, Kirsten Y, Bouwmeester, Walter, Duchesne, Inge, Pisini, Marta, Piena, Marjanne A, Damele, Francesco, Gueron, Beatrice, Treur, Maarten, Belsey, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338846/ https://www.ncbi.nlm.nih.gov/pubmed/28280374 http://dx.doi.org/10.2147/CEOR.S117650 |
Ejemplares similares
-
Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
por: Piena, Marjanne A., et al.
Publicado: (2022) -
Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis
por: Pierotti, Francesca, et al.
Publicado: (2015) -
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing–Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach
por: Piena, Marjanne A., et al.
Publicado: (2021) -
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
por: Piena, Marjanne A., et al.
Publicado: (2021) -
Suppression of Type I Interferon Signaling by Flavivirus NS5
por: Thurmond, Stephanie, et al.
Publicado: (2018)